This Pharma Giant Doesn't Want Its Drug Used in Death Penalty Executions Post author:Sam Post published:August 22, 2017 Post category:BioPharma Life Sciences Jobs … Source: BioSpace You Might Also Like Foghorn Therapeutics Launches with $50 Million March 13, 2018 Stock Plunges Despite Biohaven's Positive Migraine Data March 25, 2018 Janssen R&D Release: Data At ASCO Show Consistent Progression-Free Survival Benefit In Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients Treated With Ibrutinib, Including Those With High-Risk Disease, With Up To Four Years Of Follow-Up June 4, 2017
Janssen R&D Release: Data At ASCO Show Consistent Progression-Free Survival Benefit In Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients Treated With Ibrutinib, Including Those With High-Risk Disease, With Up To Four Years Of Follow-Up June 4, 2017